PAYLESS COMPOUNDERS, LLC

Has PAYLESS COMPOUNDERS, LLC received an FDA warning letter about GLP-1 drugs?

No FDA warning letter to PAYLESS COMPOUNDERS, LLC naming a GLP-1 drug appears in FDA’s posted letters as of Nov 15, 2026. The company is listed here because openFDA has 1 drug recall report for it naming semaglutide, the latest initiated Mar 6, 2026.

FDA records in this index name PAYLESS COMPOUNDERS, LLC on Mar 6, 2026.

Type named in FDA records
Not stated
FDA warning letters
0
Drug recall reports
1
Drugs named
Semaglutide
Latest record
Mar 6, 2026

FDA warning letters

No FDA warning letters in this index.

Drug recalls

Record
Mar 6, 2026Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Beaverton, ORLack of Assurance of SterilityClass IIOngoingD-0471-2026

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.